ALX ONCOLOGY HOLDINGS INC Increase (Decrease) in Prepaid Expense and Other Assets
ALX ONCOLOGY HOLDINGS INC (ALXO) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$929.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-06
- ALX ONCOLOGY HOLDINGS INC increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$232.00K, a 118.68% decline year-over-year.
- ALX ONCOLOGY HOLDINGS INC increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was -$697.00K.
- ALX ONCOLOGY HOLDINGS INC increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $47.00K.
- ALX ONCOLOGY HOLDINGS INC increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$53.00K.
- ALX ONCOLOGY HOLDINGS INC increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$658.00K, a 195.09% decline from fiscal 2024.
- ALX ONCOLOGY HOLDINGS INC increase (decrease) in prepaid expense and other assets for fiscal 2024 was $692.00K, a 46.40% decline from fiscal 2023.
- ALX ONCOLOGY HOLDINGS INC increase (decrease) in prepaid expense and other assets for fiscal 2023 was $1.29M, a 12.53% decline from fiscal 2022.
- ALX ONCOLOGY HOLDINGS INC increase (decrease) in prepaid expense and other assets for fiscal 2022 was $1.48M, a 11.19% decline from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$232.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$929.00K 10-Q · filed 2026-08-06 | -$882.00K derived: sum of 3 quarters · filed 2026-08-06 | -$935.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$697.00K 10-Q · filed 2026-05-08 | -$650.00K derived: sum of 2 quarters · filed 2026-05-08 | -$703.00K derived: sum of 3 quarters · filed 2026-05-08 | $539.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $47.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$6.00K derived: sum of 2 quarters · filed 2026-03-09 | $1.24M derived: sum of 3 quarters · filed 2026-08-06 | -$658.00K 10-K · filed 2026-03-09 |
| 2025-09-30 | -$53.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $1.19M derived: sum of 2 quarters · filed 2026-08-06 | -$705.00K 10-Q · filed 2025-11-07 | -$1.43M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$652.00K 10-Q · filed 2026-08-06 | -$1.38M derived: sum of 3 quarters · filed 2026-08-06 | -$6.03M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$1.89M 10-Q · filed 2026-05-08 | -$2.62M derived: sum of 2 quarters · filed 2026-05-08 | -$7.27M derived: sum of 3 quarters · filed 2026-05-08 | -$5.71M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | -$726.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$5.37M derived: sum of 2 quarters · filed 2026-03-09 | -$3.81M derived: sum of 3 quarters · filed 2026-03-09 | $692.00K 10-K · filed 2026-03-09 |
| 2024-09-30 | -$4.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$3.09M derived: sum of 2 quarters · filed 2025-11-07 | $1.42M 10-Q · filed 2025-11-07 | -$1.60M derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-06-30 | $1.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $6.07M 10-Q · filed 2025-08-12 | $3.05M derived: sum of 3 quarters · filed 2026-03-09 | $5.39M derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-03-31 | $4.50M 10-Q · filed 2025-05-08 | $1.49M derived: sum of 2 quarters · filed 2026-03-09 | $3.83M derived: sum of 3 quarters · filed 2026-03-09 | $5.96M derived: sum of 4 quarters · filed 2026-03-09 |
| 2023-12-31 | -$3.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$672.00K derived: sum of 2 quarters · filed 2026-03-09 | $1.46M derived: sum of 3 quarters · filed 2026-03-09 | $1.29M 10-K · filed 2026-03-09 |
| 2023-09-30 | $2.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $4.48M derived: sum of 2 quarters · filed 2024-11-07 | $4.31M 10-Q · filed 2024-11-07 | $3.17M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | $2.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $1.96M 10-Q · filed 2024-08-12 | $826.00K derived: sum of 3 quarters · filed 2025-03-06 | $3.24M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | -$170.00K 10-Q · filed 2024-05-09 | -$1.31M derived: sum of 2 quarters · filed 2025-03-06 | $1.11M derived: sum of 3 quarters · filed 2025-03-06 | -$271.00K derived: sum of 4 quarters · filed 2025-03-06 |
| 2022-12-31 | -$1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $1.28M derived: sum of 2 quarters · filed 2025-03-06 | -$101.00K derived: sum of 3 quarters · filed 2025-03-06 | $1.48M 10-K · filed 2025-03-06 |
| 2022-09-30 | $2.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $1.04M derived: sum of 2 quarters · filed 2023-11-13 | $2.61M 10-Q · filed 2023-11-13 | $2.23M derived: sum of 4 quarters · filed 2024-03-07 |
| 2022-06-30 | -$1.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $196.00K 10-Q · filed 2023-08-10 | -$184.00K derived: sum of 3 quarters · filed 2024-03-07 | $1.33M derived: sum of 4 quarters · filed 2024-03-07 |
| 2022-03-31 | $1.58M 10-Q · filed 2023-05-11 | $1.20M derived: sum of 2 quarters · filed 2024-03-07 | $2.71M derived: sum of 3 quarters · filed 2024-03-07 | $2.79M derived: sum of 4 quarters · filed 2024-03-07 |
| 2021-12-31 | -$380.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $1.13M derived: sum of 2 quarters · filed 2024-03-07 | $1.21M derived: sum of 3 quarters · filed 2024-03-07 | $1.66M 10-K · filed 2024-03-07 |
| 2021-09-30 | $1.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $1.59M derived: sum of 2 quarters · filed 2022-11-08 | $2.04M 10-Q · filed 2022-11-08 | $1.42M derived: sum of 4 quarters · filed 2023-03-09 |
| 2021-06-30 | $78.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $531.00K 10-Q · filed 2022-08-08 | -$92.00K derived: sum of 3 quarters · filed 2023-03-09 | $908.00K derived: sum of 4 quarters · filed 2023-03-09 |
| 2021-03-31 | $453.00K 10-Q · filed 2022-05-09 | -$170.00K derived: sum of 2 quarters · filed 2023-03-09 | $830.00K derived: sum of 3 quarters · filed 2023-03-09 | $1.04M derived: sum of 4 quarters · filed 2023-03-09 |
| 2020-12-31 | -$623.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $377.00K derived: sum of 2 quarters · filed 2023-03-09 | $583.00K derived: sum of 3 quarters · filed 2023-03-09 | $1.51M 10-K · filed 2023-03-09 |
| 2020-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $1.21M derived: sum of 2 quarters · filed 2021-11-12 | $2.14M 10-Q · filed 2021-11-12 | $1.75M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $206.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $1.14M 10-Q · filed 2021-08-12 | $753.00K derived: sum of 3 quarters · filed 2022-02-28 | $720.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $931.00K 10-Q · filed 2021-05-17 | $547.00K derived: sum of 2 quarters · filed 2022-02-28 | $514.00K derived: sum of 3 quarters · filed 2022-02-28 | |
| 2019-12-31 | -$384.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$417.00K derived: sum of 2 quarters · filed 2022-02-28 | -$744.00K 10-K · filed 2022-02-28 | |
| 2019-09-30 | -$33.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | -$360.00K 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | -$327.00K 10-Q · filed 2020-08-27 | |||
| 2018-12-31 | -$897.00K 10-K · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |